• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Canopy Growth Now Has to be Considered the Leader in the Canadian Cannabis Space

CGC has the best chance to transition to broader success should the U.S. ever go the route of legalization beyond the state level.
By STEPHEN GUILFOYLE
Apr 18, 2019 | 11:42 AM EDT
Stocks quotes in this article: CGC, ACRGF, STZ, ACB, MO, CRON

I took on the task of looking at the pending deal between Canopy Growth (CGC) , and Acreage Holdings (ACRGF) . I'll tell you what. This deal is rather complex, and really represents a right to acquire rather than an actual acquisition. The shares of both stocks are trading higher this morning, and that does make some sense. This deal would be a positive and leave not only Canopy, but Canopy's deep pocketed investor... Constellation Brands (STZ) well positioned should the use of cannabis ever attain a level of Federal legality.

The Lay of the Land

The story really begins with the November 2017 investment made in Canopy Growth by Constellation Brands that left Constellation with a 38% equity stake in the firm and a pathway toward a controlling interest over a number of years. This week's story however began on Tuesday. That day, Canopy announced an all cash purchase of Spain's Cafina. Cafina comes with a licence already in force to cultivate, distribute and export cannabis for medical and/or research purposes. This adds to Canopy's presence in Europe that already includes facilities in Germany and Denmark.

On Wednesday, Bank of America initiates coverage of both Canopy, and Aurora Cannabis (ACB) with  buy ratings. Bank of America placed target prices of $52 on CGC, and $11 on ACB. By the way, ACB is a holding of the "Stocks Under $10" portfolio that I co-manage with Chris Versace, and we were many months ahead of Bank of America with the $11 target price for ACB. Yes, that's called bragging.

Now, this complex deal. The way I read this, shareholders of ACRGF will receive an immediate aggregate payment of US $300 million, or roughly $2.55 per voting share. In addition, there will be a right, that if exercised would deliver 0.5818 share of Canopy in exchange for each one share of Acreage upon the closing of the transaction. The companies will execute a licensing agreement that grants Acreage access to Canopy's brands as well as other intellectual properties. The right, which would leave canopy with 100% control of Acreage, will become a requirement upon the federal legalization of production and distribution of cannabis in the U.S. Acreage has a licence or agreement in place to operate in 20 U.S. states, encompassing 87 dispensaries,and 22 cultivation/processing sites.

Until that time comes, the two companies will operate independently. In response to the news, Constellation Brands has announced that, while the above pending transaction is subject to Canopy Growth shareholder approval, that Constellation would agree to waive the veto rights that Constellation holds subject to certain modifications to the warrants that STZ holds as far as purchasing greater control over CGC is concerned. I could list the modifications, but I fear losing the audience.

Bottom Line?

With a deal like this in place, I think Canopy Growth now has to be considered the leader in the Canadian cannabis space with the best chance to transition to broader success should the U.S. ever go the route of legalization beyond the state level. The support of Constellation Brands cannot be understated. Sure, Altria (MO) has taken an equity stake in Cronos (CRON) , but there is far less scale in that operation.

One is quickly drawn to the year long series of lower high in CGC, couple with higher lows. This kind of action at the point of sale often leads to a violent move of some kind, without indicating direction. This morning, we may have seen that direction take shape.

It looks to me that STZ is in the process of completing a cup formation. This would be generally (or maybe just possibly) bullish in my opinion. The key here will be the stock's ability to hold the 200 day SMA, just recently captured from below, upon the next application of pressure. I can see a reason to invest in either one of these names, but not today. Not on the pop. If an investor were to look out six months that individual could probably sell October STZ 175 puts for $5.25. How's $525 in the pocket today in exchange for possibly buying the shares at a $20 discount to today's price in six month's sound? Even if forced to eat the shares, that's a net basis on $169.75. October CGC $35 puts are currently valued around $2.50. Same idea.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle had no position in the securities mentioned.

TAGS: Mergers and Acquisitions | Investing | Markets | Options | Stocks | Technical Analysis | Trading | Canada | Cannabis

More from Investing

Hits and Misses From the Early Days of What Would Become the Pandemic

Jonathan Heller
Mar 3, 2021 10:00 AM EST

Booking a cruise a year ago wasn't a great idea, but buying a discounted small-cap fund was; so was buying physical silver.

Canopy Growth Has Corrected but Needs More Accumulation

Bruce Kamich
Mar 3, 2021 9:46 AM EST

Let's review the charts and indicators.

XL Fleet's Charts Show Potential for a Future Purchase

Bruce Kamich
Mar 3, 2021 8:49 AM EST

A new base pattern needs to develop before taking a long position.

Hopping on a Couple Compelling Opportunities in a Market That Isn't

Bret Jensen
Mar 3, 2021 8:30 AM EST

Dips in the shares of Redhill Biopharma and FibroGen Inc. provided the chance for the author to employ his covered call strategy.

The Foundation for the Next Major Market Cycle Is Developing Now

James "Rev Shark" DePorre
Mar 3, 2021 7:55 AM EST

This corrective phase may go deeper, but we see some good support.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:50 AM EST PAUL PRICE

    Michaels: Close to a Deal?

    It appears that a deal could be announced soon. ...
  • 08:34 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 3/3/2021

    SPX (Long-Term View) The 20 DMA @ 3889 with the ...
  • 06:05 PM EST PAUL PRICE

    Michael's (MIK) Up on Takeover Rumors

    The NYT says talks are underway regarding a buyout...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login